JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 1, 2006; DOI: 10.1124/jpet.105.097436


0022-3565/06/3172-571-578$20.00
JPET 317:571-578, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.097436v1
317/2/571    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cha, H.-S.
Right arrow Articles by Firestein, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cha, H.-S.
Right arrow Articles by Firestein, G. S.

INFLAMMATION AND IMMUNOPHARMACOLOGY

A Novel Spleen Tyrosine Kinase Inhibitor Blocks c-Jun N-Terminal Kinase-Mediated Gene Expression in Synoviocytes

Hoon-Suk Cha1, David L. Boyle, Tomoyuki Inoue, Reineke Schoot, Paul P. Tak, Polly Pine, and Gary S. Firestein

Division of Rheumatology, Allergy and Immunology, University of California, San Diego, School of Medicine, La Jolla, California (H.-S.C., D.L.B., T.I., G.S.F.); Rigel, South San Francisco, California (P.P.); and University of Amsterdam, Amsterdam, The Netherlands (P.P.T., R.S.)

Spleen tyrosine kinase (Syk) is a key regulator of cell signaling induced by cytokines or Fc receptor engagement. However, the role of Syk in rheumatoid arthritis (RA) is not known yet. We investigated the pathways activated by Syk in tumor necrosis factor-{alpha} (TNF{alpha})-stimulated fibroblast-like synoviocytes (FLS) using the novel Syk inhibitor N4-(2,2-dimethyl-3-oxo-4H-pyrid[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine (R406). Using immunohistochemistry, Syk was detected in RA synovial tissue (ST), primarily in the synovial intimal lining. Western blot analysis demonstrated significantly greater amounts of phospho-Syk expression in RA ST compared with osteoarthritis ST. The kinase was expressed and functionally activated by TNF{alpha} in FLS and was blocked by R406. Western blot analysis demonstrated that Syk inhibition by R406 markedly suppressed TNF{alpha}-induced c-Jun N-terminal kinase (JNK) phosphorylation in FLS, with a modest decrease in extracellular signal-regulated kinase phosphorylation. Surprisingly, p38 activation was not affected by R406. The Syk inhibitor also decreased TNF{alpha}-induced mitogen-activated protein kinase kinase (MKK) 4 phosphorylation but not MKK3 and MKK6 phosphorylation, which is consistent with its selective sparing of p38. The connection between Syk and JNK was confirmed by demonstrating decreased phospho-c-Jun protein expression and complete inhibition of JNK function in R406-treated cells. R406 also suppressed downstream actions of JNK, as determined by activator protein 1 binding, as well as matrix metalloproteinase 3 gene expression. These data demonstrate that Syk activation plays an essential role in TNF{alpha}-induced cytokine and matrix metalloproteinase production in RA FLS, especially by suppressing activation of the JNK pathway.


Received October 26, 2005; accepted January 24, 2006.

Address correspondence to: Gary S. Firestein, Division of Rheumatology, Allergy and Immunology, University of California, San Diego, School of Medicine, La Jolla, CA 92093. E-mail: gfirestein{at}ucsd.edu




This article has been cited by other articles:


Home page
BloodHome page
L. Chen, S. Monti, P. Juszczynski, J. Daley, W. Chen, T. E. Witzig, T. M. Habermann, J. L. Kutok, and M. A. Shipp
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
Blood, February 15, 2008; 111(4): 2230 - 2237.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
E. Kunisch, M. Gandesiri, R. Fuhrmann, A. Roth, R. Winter, and R. W Kinne
Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF {alpha} in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis
Ann Rheum Dis, August 1, 2007; 66(8): 1043 - 1051.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
M. Hoberg, M. Rudert, T. Pap, G. Klein, S. Gay, and W. K Aicher
Attachment to laminin-111 facilitates transforming growth factor {beta}-induced expression of matrix metalloproteinase-3 in synovial fibroblasts
Ann Rheum Dis, April 1, 2007; 66(4): 446 - 451.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
T. Wossning, S. Herzog, F. Kohler, S. Meixlsperger, Y. Kulathu, G. Mittler, A. Abe, U. Fuchs, A. Borkhardt, and H. Jumaa
Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells
J. Exp. Med., December 25, 2006; 203(13): 2829 - 2840.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Braselmann, V. Taylor, H. Zhao, S. Wang, C. Sylvain, M. Baluom, K. Qu, E. Herlaar, A. Lau, C. Young, et al.
R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation
J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 998 - 1008.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
X. Wang, C. Lau, S. Wiehler, A. Pow, T. Mazzulli, C. Gutierrez, D. Proud, and C.-W. Chow
Syk Is Downstream of Intercellular Adhesion Molecule-1 and Mediates Human Rhinovirus Activation of p38 MAPK in Airway Epithelial Cells
J. Immunol., November 15, 2006; 177(10): 6859 - 6870.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.